Enzyme replacement therapy (ERT) with the form of polyethylene-glycol-modified ADA (PEG-ADA) administration displayed significant clinical improvement in adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients (11–13). This evidence concerns the gene ADA and severe combined immunodeficiency.